The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer ...

Anixa Biosciences (NASDAQ:ANIX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

Fintel reports that on March 21, 2025, Maxim Group initiated coverage of Anixa Biosciences (NasdaqCM:ANIX) with a Buy ...

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and ...

Anixa Biosciences inks LoI with VERDI Solutions to develop artificial intelligence-guided personalized and off-the-shelf peptide vaccines for cancer: San Jose, Calif Friday, March ...

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025.

Anixa Biosciences (ANIX) has entered into a letter of intent with Verdi Solutions to develop personalized and off-the-shelf peptide vaccines ...

Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $4.20. The firm’s fifty day simple moving average is $2.95 and its 200 day simple moving average is $3.01.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive ...

SAN JOSE, Calif., March 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer ...